Symptomatic treatment of multiple sclerosis

被引:103
|
作者
Henze, T.
Rieckmann, P.
Toyka, K. V.
机构
[1] Reha Zentrum Nittenau, Rehabil Zentrum Neurol, DE-93149 Nittenau, Germany
[2] Univ Wurzburg, Dept Neurol, D-8700 Wurzburg, Germany
关键词
multiple sclerosis; symptomatic treatment; consensus guidelines; expert opinion; evidence-based medicine;
D O I
10.1159/000095699
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:78 / 105
页数:28
相关论文
共 50 条
  • [11] Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry
    Skierlo, S.
    Rommer, P. S.
    Zettl, U. K.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 135 (04): : 394 - 399
  • [12] Symptomatology and symptomatic treatment in multiple sclerosis: Results from a nationwide MS registry
    Rommer, Paulus Stefan
    Eichstaedt, Kerstin
    Ellenberger, David
    Flachenecker, Peter
    Friede, Tim
    Haas, Judith
    Kleinschnitz, Christoph
    Phlau, Dieter
    Rienhoff, Otto
    Stahmann, Alexander
    Zettl, Uwe Klaus
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (12) : 1641 - 1652
  • [13] 4-Aminopyridine (Fampridine) : A new attempt for the symptomatic treatment of multiple sclerosis
    Husseini L.
    Leussink V.I.
    Kieseier B.C.
    Hartung H.-P.
    Der Nervenarzt, 2010, 81 (2) : 203 - 211
  • [14] Need for symptomatic management in advanced multiple sclerosis
    Ronning, O. M.
    Tornes, K. D.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 135 (05): : 529 - 532
  • [15] Sustained-release fampridine for symptomatic treatment of multiple sclerosis
    Korenke, Anne R.
    Rivey, Michael P.
    Allington, Douglas R.
    ANNALS OF PHARMACOTHERAPY, 2008, 42 (10) : 1458 - 1465
  • [16] Symptomatic cranial neuralgias in multiple sclerosis: Clinical features and treatment
    De Santi, Lorenzo
    Annunziata, Pasquale
    CLINICAL NEUROLOGY AND NEUROSURGERY, 2012, 114 (02) : 101 - 107
  • [17] Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment
    Romani, A
    Bergamaschi, R
    Candeloro, E
    Alfonsi, E
    Callieco, R
    Cosi, V
    MULTIPLE SCLEROSIS JOURNAL, 2004, 10 (04) : 462 - 468
  • [18] Multiple sclerosis: Symptomatic therapies
    Metz, L
    SEMINARS IN NEUROLOGY, 1998, 18 (03) : 389 - 395
  • [19] Symptomatic therapy in multiple sclerosis
    Giovanni Luigi Mancardi
    Neurological Sciences, 2006, 27 : s287 - s287
  • [20] Symptomatic Management in Multiple Sclerosis
    Samkoff, Lawrence M.
    Goodman, Andrew D.
    NEUROLOGIC CLINICS, 2011, 29 (02) : 449 - +